Wu Duojia, Ni Jie, Beretov Julia, Cozzi Paul, Willcox Mark, Wasinger Valerie, Walsh Bradley, Graham Peter, Li Yong
Cancer Care Centre, St. George Hospital, Kogarah, NSW 2217, Australia; St George and Sutherland Clinical School, Faculty of Medicine, UNSW Sydney, NSW 2052, Australia.
Cancer Care Centre, St. George Hospital, Kogarah, NSW 2217, Australia; St George and Sutherland Clinical School, Faculty of Medicine, UNSW Sydney, NSW 2052, Australia; SEALS, Anatomical Pathology, St. George Hospital, Kogarah, NSW 2217, Australia.
Crit Rev Oncol Hematol. 2017 Oct;118:15-26. doi: 10.1016/j.critrevonc.2017.08.002. Epub 2017 Aug 19.
Prostate cancer (CaP) is the most common cancer in men and the second leading cause of cancer deaths in males in Australia. Although serum prostate-specific antigen (PSA) has been the most widely used biomarker in CaP detection for decades, PSA screening has limitations such as low specificity and potential association with over-diagnosis. Current biomarkers used in the clinic are not useful for the early detection of CaP, or monitoring its progression, and have limited value in predicting response to treatment. Urine is an ideal body fluid for the detection of protein markers of CaP and is emerging as a potential source for biomarker discovery. Gene-based biomarkers in urine such as prostate cancer antigen-3 (PCA3), and genes for transmembrane protease serine-2 (TMPRSS2), and glutathione S-transferase P (GSTP1) have been developed and evaluated in the past decades. Among these biomarkers, urinary PCA3 is the only one approved by the FDA in the USA for clinical use. The study of urine microRNAs (miRNAs) is another burgeoning area for investigating biomarkers to achieve a pre-biopsy prediction of CaP to contribute to early detection. The development of mass spectrometry (MS)-based proteomic techniques has sparked new searches for novel protein markers for many diseases including CaP. Urinary biomarkers for CaP represent a promising alternative or an addition to traditional biomarkers. Future success in biomarker discovery will rely on collaboration between clinics and laboratories. In addition, research efforts need to be moved from biomarker discovery to validation in a large cohort or separate population of patients and translation of these findings to clinical practice. In this review, we discuss urine as a potential source for CaP biomarker discovery, summarise important genetic urine biomarkers in CaP and focus on MS-based proteomic approaches as well as other recent developments in quantitative techniques for CaP urine biomarker discovery.
前列腺癌(CaP)是男性中最常见的癌症,也是澳大利亚男性癌症死亡的第二大主要原因。尽管几十年来血清前列腺特异性抗原(PSA)一直是CaP检测中使用最广泛的生物标志物,但PSA筛查存在局限性,如特异性低以及可能与过度诊断相关。目前临床使用的生物标志物对CaP的早期检测或病情进展监测并无帮助,在预测治疗反应方面价值有限。尿液是检测CaP蛋白质标志物的理想体液,正逐渐成为生物标志物发现的潜在来源。过去几十年中,已开发并评估了尿液中基于基因的生物标志物,如前列腺癌抗原3(PCA3)、跨膜蛋白酶丝氨酸2(TMPRSS2)基因和谷胱甘肽S转移酶P(GSTP1)基因。在这些生物标志物中,尿PCA3是美国食品药品监督管理局(FDA)批准可用于临床的唯一一种。尿液微小RNA(miRNA)的研究是另一个新兴领域,用于研究生物标志物以实现对CaP的活检前预测,从而有助于早期检测。基于质谱(MS)的蛋白质组学技术的发展引发了对包括CaP在内的许多疾病新型蛋白质标志物的新探索。CaP的尿液生物标志物是传统生物标志物的一种有前景的替代物或补充。生物标志物发现的未来成功将依赖于临床与实验室之间的合作。此外,研究工作需要从生物标志物发现转向在大量队列或不同患者群体中的验证,并将这些发现转化为临床实践。在本综述中,我们讨论尿液作为CaP生物标志物发现的潜在来源,总结CaP中重要的尿液基因生物标志物,并重点关注基于MS的蛋白质组学方法以及CaP尿液生物标志物发现定量技术的其他最新进展。